Codes, standards and practices
Novo Nordisk strives to communicate effectively with all its stakeholders and holds itself accountable to stakeholders for the company’s performance. We maintain open, respectful, timely and transparent communication and reporting. The company’s reporting on financial and non-financial performance meets current global reporting standards (such as the IFRS and the GRI Sustainability Reporting Guidelines) and seeks inspiration from best practice. The accuracy, completeness and reliability of the information provided is verified through internal controls, independent audits and assurance.
As an international company listed on the stock exchanges in Copenhagen, New York and London, Novo Nordisk is in compliance with Danish, US and UK securities laws, with the Danish Recommendations on Corporate Governance, and is in general in compliance with corporate governance standards in New York and London.
Compliance is supported by company standards and a set of management tools that drive and monitor performance. According to one of the Fundamentals: ‘Every manager must establish and maintain procedures in the unit for living up to relevant laws, regulations, and group commitments.’
The Novo Nordisk Way of Management forms the values-based governance framework for the company. From Vision to policies, it explicates how values are put into action. It is sufficiently specific to guide decision-making, yet at the same time allows for the adoption of new, supporting guidelines, policies or practices in response to evolving societal expectations or business developments.
The Novo Nordisk Way of Management also specifies the commitments to financial, environmental and social responsibility. This includes subscribing to:
- The International Chamber of Commerce’s Charter for Sustainable Development
- The United Nations Convention on Biological Diversity
- The United Nations Universal Declaration of Human Rights
- The United Nations Global Compact
Beyond compliance with international and national legislation and regulations and with local authorities, Novo Nordisk subscribes to a number of voluntary codes and standards.
Below is a listing of those that are deemed most relevant:
Securities laws
As an international company listed on the stock exchanges in Copenhagen, New York and London, Novo Nordisk is in compliance with Danish, US and UK securities laws.
Corporate Governance
Novo Nordisk is in compliance with the Danish Recommendations on Corporate Governance, and is in general in compliance with corporate governance standards on the New York and London Stock Exchanges.
Reporting and disclosure
Novo Nordisk has chosen an integrated approach to reporting on its financial and non-financial performance. Hence, reporting follows current international standards in terms of both mandatory and voluntary reporting. The information is audited and assured.
IFRS
Novo Nordisk’s financial accounting principles comply with International Financial Reporting Standards (IFRS).
Sarbanes-Oxley
Novo Nordisk is in full compliance with the requirements for documenting and reporting performance spelled out by the Sarbanes-Oxley Act. Novo Nordisk provides this information in its Form 20-F, which is expected to be submitted in mid-February 2006.
AA1000 Framework
Novo Nordisk’s non-financial reporting follows the accountability standard AA1000 Framework. This states that reporting must provide a complete, accurate, relevant and balanced picture of the organisation’s approach to and impact on society. The report is assured against the AA1000 Assurance Standard.
Global Reporting Initiative Guidelines
Novo Nordisk reports – and has done so since 2002 – in accordance with the Global Reporting Initiative’s (GRI’s) 2002 Sustainability Reporting Guidelines. The Guidelines require reporting in accordance with 11 principles and against a list of 142 indicators, including 97 sustainability performance indicators.
Novo Nordisk supports the GRI – as an Organisational Stakeholder – and its initiatives to drive sustainability reporting. This includes support to the new G3 Guidelines and appreciation of the improvements it represents.
It was not possible for Novo Nordisk to adopt the G3 Guidelines for the 2006 reporting cycle, as this is tied in with the calendar year. Adoption of the G3 is part of the company’s 5-year reporting strategy – to be framed during 2007.
Global Compact
Novo Nordisk is (since 2002) a signatory to the United Nations Global Compact, a platform for promoting good corporate principles and learning in the areas of human rights, labour, environment and anti-corruption. The company reports on actions to implement its 10 principles during 2006 in a Communication on Progress, including performance metrics aligned with the GRI Guidelines.
Other codes and standards that Novo Nordisk subscribes to are:
UN Convention against Corruption (2005)
UN Universal Declaration of Human Rights (1999)
International Chamber of Commerce Business Charter for Sustainable Development (1999)
Environmental management ISO 14001
Biopharmaceuticals
- Site Gentofte
- Pharmaceutical Site Måløv
- Site Factor VII
Devices & Sourcing
- Device Manufacturing & Sourcing
- Needle Manufacturing & Sourcing
- Local Manufacturing & Sourcing
- Koriyama Factory, Japan
- FeF Chemicals
Diabetes API
- Manufacturing Development
- Insulin API Manufacturing I
- Insulin API Manufacturing II
- Purification Plants
- Diabetes API, QA
Diabetes Finished Products
- Diabetes API, QC NNPII, Clayton, USA
- DFP Site Bagsværd
- DFP Site Hillerød
- DFP Site Kalundborg
- Logistics
- NNPSA, Chartres, France
As a pharmaceutical company, Novo Nordisk is regulated by the FDA. This also regulates quality, advertising and marketing. In addition, the company has implemented the following certified management systems:
Quality Management ISO9000
Novo Nordisk’s production is certified according to the ISO9000 standard.
Organisational Health and Safety
In 2006 Novo Nordisk adopted a management system certified according to OHSAS18001 for Novo Nordisk in Denmark and Product Supply globally.
Marketing practices
Novo Nordisk subscribes to the WHO Ethical Criteria for Medicinal Drug Promotion. Furthermore, the company’s policies and procedures are in accordance with the principles of industry codes of practices, such as the PhRMA, EFPIA, IFPMA, JPMA marketing codes.
Accolades
In January 2006, Novo Nordisk signed an agreement with WWF that made the company a member of the Climate Savers programme. Under this agreement Novo Nordisk has set an ambitious target for the company’s CO2 reductions: to achieve a reduction of 10% of its CO2 emissions by 2014 compared to 2004.
Novo Nordisk continues to maintain its lead in the Climate Leadership Index. The company strategy and approach have been rated well within the sector. While the leadership index and methodology had changed in 2006 to focus on the 10 highest carbon impact sectors, the project still continues to rate carbon strategies in each sector.
See a list of awards for the company’s sustainability-driven activities.
This page has been assessed by PricewaterhouseCoopers as part of its assessment of Novo Nordisk’s statement that it reports ‘in accordance’ with GRI. Please refer to Audit and assurance for a full description of the nature of assurance offered.
